D-dimer testing to determine the duration of anticoagulation therapy

Area of Science:

• Hematology
• Vascular Medicine
• Clinical Thrombosis

Background:

• The optimal duration of anticoagulation for idiopathic venous thromboembolism (VTE) remains unclear.
• D-dimer testing may aid in determining the need for extended anticoagulation therapy.

Purpose of the Study:

• To investigate the utility of D-dimer testing in guiding anticoagulation decisions after an initial treatment course for VTE.
• To assess the risk of VTE recurrence and major bleeding based on D-dimer levels post-anticoagulation.

Main Methods:

• D-dimer levels were measured 1 month after discontinuing anticoagulation in patients with unprovoked proximal deep-vein thrombosis or pulmonary embolism.
• Patients with normal D-dimer did not resume anticoagulation; those with abnormal D-dimer were randomized to resume or discontinue treatment.
• The composite outcome of recurrent VTE and major bleeding was tracked over a mean follow-up of 1.4 years.

Main Results:

• D-dimer was abnormal in 36.7% of patients. Among those who stopped anticoagulation, 15.0% experienced an event compared to 2.9% who resumed (HR 4.26).
• Recurrent VTE occurred in 6.2% of patients with normal D-dimer levels.
• Patients with abnormal D-dimer who stopped anticoagulation had a 2.27-fold increased risk of recurrence versus those with normal D-dimer (P=0.02).

Conclusions:

• An abnormal D-dimer level 1 month post-anticoagulation discontinuation is associated with a significant risk of VTE recurrence.
• Resuming anticoagulation in patients with abnormal D-dimer levels effectively reduces the recurrence rate.
• The management strategy for patients with normal D-dimer levels requires further investigation.